200 related articles for article (PubMed ID: 28234344)
21. RAS mutations are uncommon in multiple myeloma and other monoclonal gammopathies.
Martín P; Santón A; García-Cosío M; Bellas C
Int J Oncol; 2005 Oct; 27(4):1023-8. PubMed ID: 16142319
[TBL] [Abstract][Full Text] [Related]
22. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.
Bataille R; Jourdan M; Zhang XG; Klein B
J Clin Invest; 1989 Dec; 84(6):2008-11. PubMed ID: 2592570
[TBL] [Abstract][Full Text] [Related]
23. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management.
Rajkumar SV
Hematology Am Soc Hematol Educ Program; 2005; ():340-5. PubMed ID: 16304401
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
25. Malignant transformation in IgM monoclonal gammopathy of undetermined significance.
Montoto S; Rozman M; Rosiñol L; Nadal E; Giné E; Aymerich M; Ferrer A; Esteve J; Bosch F; López-Guillermo A; Bladé J; Montserrat E
Semin Oncol; 2003 Apr; 30(2):178-81. PubMed ID: 12720132
[TBL] [Abstract][Full Text] [Related]
26. Multiple myeloma arising from monoclonal gammopathy of undetermined significance in a patient with Gaucher's disease.
Brady K; Corash L; Bhargava V
Arch Pathol Lab Med; 1997 Oct; 121(10):1108-11. PubMed ID: 9341594
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
28. Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma.
Chim CS; Liang R; Leung MH; Kwong YL
J Clin Pathol; 2007 Jan; 60(1):104-6. PubMed ID: 17213358
[TBL] [Abstract][Full Text] [Related]
29. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.
Maura F; Petljak M; Lionetti M; Cifola I; Liang W; Pinatel E; Alexandrov LB; Fullam A; Martincorena I; Dawson KJ; Angelopoulos N; Samur MK; Szalat R; Zamora J; Tarpey P; Davies H; Corradini P; Anderson KC; Minvielle S; Neri A; Avet-Loiseau H; Keats J; Campbell PJ; Munshi NC; Bolli N
Leukemia; 2018 Apr; 32(4):1044-1048. PubMed ID: 29209044
[No Abstract] [Full Text] [Related]
30. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
[TBL] [Abstract][Full Text] [Related]
31. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF
Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070
[TBL] [Abstract][Full Text] [Related]
32. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma.
Woitge HW; Pecherstorfer M; Horn E; Keck AV; Diel IJ; Bayer P; Ludwig H; Ziegler R; Seibel MJ
Br J Cancer; 2001 Feb; 84(3):344-51. PubMed ID: 11161399
[TBL] [Abstract][Full Text] [Related]
33. The Incidence of Senile Cataract and Glaucoma is Increased in Patients with Plasma Cell Dyscrasias: Etiologic Implications.
Hemminki K; Försti A; Tuuminen R; Hemminki O; Goldschmidt H; Sundquist K; Sundquist J; Li X
Sci Rep; 2016 Jun; 6():28500. PubMed ID: 27328652
[TBL] [Abstract][Full Text] [Related]
34. Vitamin D and plasma cell dyscrasias: reviewing the significance.
Burwick N
Ann Hematol; 2017 Aug; 96(8):1271-1277. PubMed ID: 28502031
[TBL] [Abstract][Full Text] [Related]
35. [A long-term observation of development from monoclonal gammopathy of undetermined significance (MGUS) into primary amyloidosis].
Kanoh T; Yago K; Okuma M
Rinsho Ketsueki; 1990 Oct; 31(10):1740-4. PubMed ID: 2255066
[TBL] [Abstract][Full Text] [Related]
36. CD44 isoforms are differentially regulated in plasma cell dyscrasias and CD44v9 represents a new independent prognostic parameter in multiple myeloma.
Eisterer W; Bechter O; Hilbe W; van Driel M; Lokhorst HM; Thaler J; Bloem AC; Günthert U; Stauder R
Leuk Res; 2001 Dec; 25(12):1051-7. PubMed ID: 11684276
[TBL] [Abstract][Full Text] [Related]
37. [Immunoglobulin heavy chain gene rearrangements in the monoclonal gammopathies].
Bosaleh A; Denninghoff V; Garcia A; Rescia C; Avagnina A; Elsner B
Medicina (B Aires); 2005; 65(3):219-25. PubMed ID: 16042132
[TBL] [Abstract][Full Text] [Related]
38. RAS gene mutations in multiple myeloma and related monoclonal gammopathies.
Matozaki S; Nakagawa T; Nakao Y; Fujita T
Kobe J Med Sci; 1991 Feb; 37(1):35-45. PubMed ID: 1921261
[TBL] [Abstract][Full Text] [Related]
39. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis.
Bezieau S; Devilder MC; Avet-Loiseau H; Mellerin MP; Puthier D; Pennarun E; Rapp MJ; Harousseau JL; Moisan JP; Bataille R
Hum Mutat; 2001 Sep; 18(3):212-24. PubMed ID: 11524732
[TBL] [Abstract][Full Text] [Related]
40. Burden of cytogenetically abnormal plasma cells in light chain amyloidosis and their prognostic relevance.
Kim SY; Im K; Park SN; Kim JA; Yoon SS; Lee DS
Leuk Res; 2016 May; 44():45-52. PubMed ID: 27015231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
